Format

Send to

Choose Destination
See comment in PubMed Commons below
J Am Acad Dermatol. 2007 Nov;57(5):767-74. Epub 2007 Aug 29.

A multicenter, randomized, placebo-controlled, double-blind clinical trial of a novel formulation of 5% minoxidil topical foam versus placebo in the treatment of androgenetic alopecia in men.

Author information

1
Duke University Medical Center, Durham, North Carolina 27516, USA. olsen001@mc.duke.edu

Abstract

BACKGROUND:

An alternative to currently marketed topical minoxidil solutions is desirable.

OBJECTIVE:

To assess the efficacy and safety of a new 5% minoxidil topical formulation in a propylene glycol-free foam vehicle in men with androgenetic alopecia (AGA).

METHODS:

This was a 16-week, double-blind, placebo-controlled trial of 5% minoxidil topical foam (MTF) in 352 men, 18 to 49 years old. At week 16, 143 subjects continued on an open-label phase to collect 52 weeks of safety information on 5% MTF.

RESULTS:

At week 16 compared with baseline, there was a statistically significant increase in (1) hair counts in the 5% MTF group versus placebo (P < .0001) and (2) subjective assessment of improved hair loss condition (P < .0001) in the 5% MTF group versus placebo. The 5% MTF was well tolerated over a 52-week period.

LIMITATIONS:

There was no collection of efficacy data beyond 16 weeks.

CONCLUSIONS:

We believe that 5% MTF is a safe and effective treatment for men with AGA.

PMID:
17761356
DOI:
10.1016/j.jaad.2007.04.012
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center